Peter Probst

USPTO Granted Patents = 18 (Patent Applications = 10)

EPO Patents = 2 (Patent Applications = 11)

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 129(Granted Patents)

Company Filing History:

Leland Stanford Junior University

patents

4. 1 out of 531

Glaxosmithkline Biologicals Sa

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195549 - Immunomodulatory antibodies and methods of use thereof (2025-01-14),

2. 11827715 - Human CD163 antibodies and uses thereof (2023-11-28),

3. 11634501 - Immunomodulatory antibodies and methods of use thereof (2023-04-25),

4. 11034770 - Immunomodulatory antibodies and methods of use thereof (2021-06-15),

5. 8541007 - Vaccines against chlamydial infection (2013-09-24),

6. 8377448 - CD47 related compositions and methods for treating immunological diseases and disorders (2013-02-19),

7. 8263089 - Compounds and methods for treatment and diagnosis of chlamydial infection (2012-09-11),

8. 8052975 - Compounds and methods for treatment and diagnosis of chlamydial infection (2011-11-08),

9. 7462357 - Compounds and methods for treatment and diagnosis of chlamydial infection (2008-12-09),

10. 7384638 - Compounds and methods for treatment and diagnosis of Chlamydial infection (2008-06-10),

11. 6638517 - Leishmania antigens for use in the therapy and diagnosis of leishmaniasis (2003-10-28),

12. 6613337 - Leishmania antigens for use in the therapy and diagnosis of leishmaniasis (2003-09-02),

13. 6607731 - Leishmania antigens for use in the therapy and diagnosis of leishmaniasis (2003-08-19),

14. 6555115 - Compounds and methods for treatment and diagnosis of chlamydial infection (2003-04-29),

15. 6447779 - Compounds for the diagnosis of Chlamydial infection (2002-09-10),

Title: Innovations of Peter Probst in Immunomodulatory Antibodies

Introduction

Peter Probst is a prominent inventor based in Seattle, WA, with a significant portfolio of 18 patents to his name. His work largely focuses on immunomodulatory antibodies, which have promising implications in cancer treatment. Probst's contributions to the field mark him as a key player in medical innovations.

Latest Patents

Among his latest innovations, Probst has developed two notable patents:

1. **Immunomodulatory Antibodies and Methods of Use Thereof** - This patent details antibodies that bind specifically to CD163 on cells, particularly macrophages. These antibodies are intended for use in treatment methodologies, especially for combating cancer.

2. **Human CD163 Antibodies and Uses Thereof** - Similar to the first, this patent presents antibodies that target CD163 on certain cells. This invention reinforces the applicability of these antibodies in therapeutic strategies for cancer treatment.

Career Highlights

Probst has had a distinguished career with significant tenure at renowned companies. He has contributed his expertise to organizations such as Corixa Corporation and OncoResponse, Inc. His innovative strategies and commitment to research have greatly influenced the development of immunotherapies in the field of oncology.

Collaborations

Throughout his career, Probst has collaborated with various talented professionals, including Ajay Bhatia and Yasir A W Skeiky. These partnerships have fostered a dynamic environment that encourages the exchange of ideas, ultimately enhancing the quality and impact of their innovations.

Conclusion

Peter Probst stands out as an accomplished inventor in the realm of antibodies and cancer treatment. His significant contributions to the science of immunomodulation not only reflect his expertise but also his commitment to advancing medical therapies. With 18 patents and a proven track record, Probst is undoubtedly a vital force in shaping future innovations in healthcare.

This text is generated by artificial intelligence and may not be accurate.